EW · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $88.83, EW requires a 4% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 15%.
The ranked statistic lives on the growth axis and the axes AGREE (+11.74pp margin-axis slack against +11.45pp growth-axis), so the declaration is reported rather than load-bearing.
The value rests on an exit multiple of 30.3x, a terminal operating margin of 27% and a 7.7% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: CMS finalises the TAVR NCD retaining hospital volume floors and the two-operator requirement, so the site-expansion mechanism that underwrites TAVR's re-acceleration does not open; AND PROGRESS reads out negative for moderate aortic stenosis at TCT in Q4 2026, capping disease-stage expansion rather than delaying it.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The ranked statistic lives on the growth axis and the axes AGREE (+11.74pp margin-axis slack against +11.45pp growth-axis), so the declaration is reported rather than load-bearing. |
| What do we forecast? | Revenue growth of 15% demonstrated; a terminal operating margin of 27%; an exit multiple of 30.3x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +10.4 percentage points. |
| What is it worth? | Twelve-month target $98.98, +11% from the struck price. Scenario-weighted expected return net of costs +11.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| through FY2027 | The TAVR re-acceleration leg (disease-stage expansion + site… | TAVR constant-currency sales growth at or above 5.0% y/y in two consecutive quarters | TAVR constant-currency sales growth below 5.0% y/y in two consecutive quarters |
| FY2026 / FY2027 | The second-platform reinvestment mechanism that closes the COMPOUNDER… | TMTT sales at or above $760m for FY2026, or below $950m for FY2027 | TMTT sales below $760m for FY2026, or below $950m for FY2027 |
| FY2027 | The 27.0% terminal margin, and by implication the STATE A… | GAAP operating margin at or above 25.0% in two consecutive quarters, with no add-backs permitted | GAAP operating margin below 25.0% in two consecutive quarters, with no add-backs permitted |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
CMS finalises the TAVR NCD retaining hospital volume floors and the two-operator requirement, so the site-expansion mechanism that underwrites TAVR's re-acceleration does not open; AND PROGRESS reads out negative for moderate aortic stenosis at TCT in Q4 2026, capping disease-stage expansion rather than delaying it. TAVR growth falls to low single digits, TMTT's ramp cannot offset a $4.9bn base, and the multiple resets toward the identity floor on a lower earnings base.
Estimated probability 15%, against the 29% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when forward 12-month E[R] falls below zero net of costs, OR when the NTM EV/EBIT multiple exceeds 35.95x - the 5-year p75 of EW's own distribution - at which point the name is priced above its own post-derating range and the thesis has been paid. On approach to the $98.98 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | CMS finalises the TAVR NCD retaining hospital volume floors and the two-operator requirement, so the site-expansion mechanism that underwrites TAVR's re-acceleration does not open; AND PROGRESS reads out negative for moderate aortic stenosis at TCT in Q4 2026, capping disease-stage expansion rather than delaying it. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +10.4 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: CMS finalises the TAVR NCD retaining hospital volume floors and the two-operator requirement, so the site-expansion mechanism that underwrites TAVR's re-acceleration does not open; AND PROGRESS reads out negative for moderate aortic stenosis at TCT in Q4 2026, capping disease-stage expansion rather than delaying it. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $78.17, which forces an immediate review.